Pre-validated clinical study programs, in vitro toxicological evaluations, and botanical potency profiling engineered to meet Egyptian Drug Authority (EDA) and ICH-GCP rigor.
Strategic convergence of Vision 2030 healthcare modernizations, localized generic substitutions, and stringent regulatory compliance under the Egyptian Drug Authority (EDA).
The enforcement of Egypt's Law No. 214 of 2020 on Clinical Medical Research has shifted clinical governance into strict alignment with ICH-GCP. Pharmaceutical sponsors operating within Cairo, Alexandria, and Tenth of Ramadan City require validated preclinical toxicity documentation, bioequivalence (BE) assays, and traceable multicenter trials to clear ministerial registrations.
Egyptian consumers display historic confidence in botanical formulations and phytomedicines. With national agendas curbing reliance on imported active pharmaceutical ingredients (APIs), domestic Egyptian manufacturers are heavily investing in standardized, evidence-based herbal derivatives backed by verified animal assays and human clinical dossiers.
The commissioning of Gypto Pharma (Medicine City) highlights Egypt's ambitions to become an undisputed regional production powerhouse for Africa and the Middle East. Achieving these export ambitions necessitates rigorous validation of raw botanicals, molecular fingerprinting, and Phase I–IV clinical dossiers that comply with global benchmarks.
Bridging deep phytochemical synthesis and high-throughput analytical testing with seamless batch-to-batch consistency and economical contract research capabilities.
MedGence (Yineng Pharma) operates tier-one laboratories in Changsha, China, staffed by over 300 experienced research pharmacologists, toxicologists, and chromatographic specialists. With over 14+ years of dedicated phytochemical R&D, we transform empirical traditional natural formulas into modern, data-backed pharmacological assets ready for multinational regulatory scrutiny.
Unlike conventional brokers, our integrated pilot facilities and collaborative synthesis plants bridge the notoriously difficult transition from bench assay to commercial manufacturing. Egyptian partners retain 100% intellectual property certainty under strictly enforced bilateral non-disclosure frameworks and certified audit trails.
We deploy validated High-Performance Liquid Chromatography (HPLC), High-Performance Thin-Layer Chromatography (HPTLC), Gas Chromatography (GC), and fingerprint spectrometry to isolate active fractions, quantify marker phytochemicals, and eliminate heavy metals, residual solvents, or agricultural contaminants.
Conducting in vitro receptor-binding assays, acute and sub-chronic animal toxicity trials (LD50), and human clinical batch preparation through our China supply network reduces overall sponsor expenditure by up to 50% compared to Western European alternatives, without forfeiting quality or safety indices.
A unified development matrix designed to de-risk market registration filings before international regulatory authorities and the Egyptian Drug Authority.
| Development Phase | Technical Workflows | Instrumentation & Toolsets | Egyptian Regulatory Alignment |
|---|---|---|---|
| 01. Discovery & Screening | Fractionation, phytochemical profile mapping, primary receptor binding, antioxidant/anti-inflammatory assays. | LC-MS/MS, High-Resolution GC, In Silico Molecular Docking. | Baseline chemical identity confirmation; screening out unauthorized botanical species. |
| 02. Method Standardization | Qualitative and quantitative assay validation, batch reproducibility profiles, shelf-life testing. | HPTLC, HPLC-DAD, UV-Vis Spectrophotometry, Fingerprint Arrays. | Compliant with Egyptian Pharmacopoeia and EDA quality monographs. |
| 03. Preclinical In Vitro / In Vivo | Acute oral LD50, repeated-dose sub-chronic toxicity (28/90 days), Ames test, chromosomal aberration. | Specific-Pathogen-Free (SPF) animal suites, flow cytometry, microplate readers. | Toxicological dossier preparation under Law 214/2020 preclinical safety standards. |
| 04. Clinical Studies (I–IV) | First-in-Human (FIH) tolerability, PK/PD parameters, double-blind randomized clinical trials (RCTs), post-marketing pharmacovigilance. | GCP-audited clinical trial data management (EDC), centralized bioanalytical centers. | Ready for submission to Egyptian Ethics Committees & Central Administration of Pharmaceutical Affairs. |
| 05. Pilot & Commercial CDMO | Supercritical fluid extraction, spray drying, granulation, finished dosage encapsulation, tableting, liquids. | GMP extraction lines, rotary tablet presses, aseptic liquid bottling suites. | Direct container shipments to Port of Alexandria, Port Said, and Sokhna Port with COA & CTD dossiers. |
Addressing prominent public health priorities, chronic metabolic conditions, and expanding wellness markets across Greater Cairo and the broader MENA territory.
Given the elevated prevalence of Type-2 diabetes and metabolic syndromes within Egypt, our clinical research division supports botanical fraction evaluation (e.g., berberine, fenugreek polyphenols, cinnamon extract) via targeted in vitro alpha-glucosidase inhibition and controlled human Phase II glycemic stabilization studies.
Following national health campaigns eradicating Hepatitis C, maintaining hepatic vitality remains a high consumer priority. MedGence formulates clinical protocols documenting silymarin derivatives, artemisinin co-factors, and schisandra extracts with proven transaminase-lowering efficacy verified across rodent and patient cohorts.
Egyptian retailers, pharmacy chains, and contract packing brands require fast-to-shelf, verified immunity formulations. We supply fully characterized active concentrates and run short-cycle human trial efficacy verification programs for respiratory support, joint mobility, and cognitive health.
Key information regarding bioequivalence, trial transfers, sample delivery, and commercial manufacturing contracts.
Explore our complete catalog of certified laboratory studies, potency assessments, active compound screenings, and full-scale clinical trials serving corporate clients worldwide and across Egypt.
